Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C (Business Wire via Yahoo! Finance)
CAMBRIDGE, Mass.----Idera Pharmaceuticals today announced that the first patient has been dosed in a Phase 1 trial evaluating IMO-2125 for the treatment of patients with hepatitis C virus infection.
DOR BioPharma Announces Initiation of GI Radiation Injury Program Pursuant to $1 Million NIH Grant (Marketwire via Yahoo! Finance)
DOR BioPharma, Inc. announced today that its academic partner, the Fred Hutchinson Cancer Research Center, has received a $1 million grant from the National Institute of Health to conduct preclinical studies of oral Beclomethasone Dipropionate for the treatment of gastrointestinal radiation injury.
DOR BioPharma Announces Initiation of GI Radiation Injury Program Pursuant to $1 Million NIH Grant (Marketwire via Yahoo! Finance)
DOR BioPharma, Inc. announced today that its academic partner, the Fred Hutchinson Cancer Research Center, has received a $1 million grant from the National Institute of Health to conduct preclinical studies of oral Beclomethasone Dipropionate for the treatment of gastrointestinal radiation injury.
Original post: Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C (Business Wire via Yahoo! Finance) by Copyright (c) 2004 Yahoo! Inc. All rights reserved. at Yahoo! News Search Results for allergy and asthma associate
Blog tag: Allergy and asthma associate
Technorati tag: Allergy and asthma associate